Research on prevention and treatment of hemorrhagic fevers

Annals of Agricultural and Environmental Medicine

Volumn 19, Issue 2, 2012, Pages 165-171

  Joniec, Justyna ^a   Kołodziej, Marcin ^a   Bartoszcze, Michał ^a   Kocik, Janusz ^a   Knap, Józef ^b  

^a MILITARY INSTITUTE OF HYGIENE AND EPIDEMIOLOGY   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Antivirals; Hemorrhagic fevers; Vaccines; Viruses

Indexed keywords

3 DEAZAADENOSINE; 3 DEAZANEPLANOCIN A; ADENOSINE DERIVATIVE; ALTERNATHERA PHILOXCROIDES EXTRACT; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; ARBIDOL; CHLORPROMAZINE; CYANOVIRIN N; DENGUE VACCINE; EBOLA VACCINE; FAVIPIRAVIR; FGI 106; GALACTOMANNAN; HIPPOPHAE RHAMNOIDES EXTRACT; IMMUNOLOGICAL ADJUVANT; MP 12; N ACETYL S NITROSOPENICILLAMINE; N1 3 FLUOROPHENYL HYPOXANTHINE; N1 3 FLUOROPHENYL INOSINE; PLANT EXTRACT; POLYSACCHARIDE; RECOMBINANT VACCINE; RIBAVIRIN; TRIFLUOPERAZINE; UNCARIA TOMENTOSA EXTRACT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS LIKE PARTICLE VACCINE; VIRUS VACCINE; YELLOW FEVER VACCINE;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CHIKUNGUNYA; DENGUE; DOSE RESPONSE; DRUG RESEARCH; DRUG SCREENING; EBOLA HEMORRHAGIC FEVER; GENETIC ENGINEERING; HEMORRHAGIC FEVER WITH RENAL SYNDROME; HUMAN; IMMUNOMODULATION; INFECTION PREVENTION; INFECTION RISK; INFLUENZA; NONHUMAN; RESPIRATORY TRACT DISEASE; RIFT VALLEY FEVER; SINGLE DRUG DOSE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VACCINATION; VIRUS HEMORRHAGIC FEVER; VIRUS REPLICATION; VIRUS TRANSMISSION; YELLOW FEVER;

ANIMALS; ANTIVIRAL AGENTS; HEMORRHAGIC FEVERS, VIRAL; HUMANS; MICE; RATS; RNA VIRUSES;

ALGAE; ARENAVIRIDAE; BUNYAVIRIDAE; FILOVIRIDAE; FLAVIVIRIDAE; RNA VIRUSES;

EID: 84863515630     PISSN: 12321966     EISSN: 18982263     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Geisbert T W, Lee ACH, Robbins M, Geisbert JB, Honko AN, Sood V et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 2010; 375: 1896-905.
2. http://www.cdc.gov/ncidod/dvrd/spb/mnpages/dispages/ebola/ebolatable.htm (access: 2011.09.27).
3. http://www.cdc.gov/ncidod/dvrd/spb/mnpages/dispages/marburg/marburgtable.htm (access: 2011.09.27).
4. http://www.who.int/mediacentre/factsheets/fs100/en/ (access: 2011.09.27).
5. http://www.cdc.gov/dengue/epidemiology/index.html (access: 2011.09.27).
6. http://www.who.int/mediacentre/factsheets/fs117/en/index.html (access: 2011.09.27).
7. Mirski T, Bartoszcze M, Bielawska-Drózd A. Globalizacja a choroby zakazne. Przegl Epidemiol 2011;65(4):651-658.
8. Woodrow CJ, Eziefula AC, Agranioff D, Scott GM, Watson J, Chiodini PL et al. Early risk assessment for viral haemorrhagic fever: experience at the Hospital for tropical diseases. J Infection. 2007; 54: 6-11.
9. Borio L, Inglesby T, Peters CJ, Alan L, Schmaljohn L, James MH et al. Hemorrhagic fever viruses as biological weapons medical and public health management. JAMA 2002; 287(18): 2391-2405.
10. Talarico LB, Pujol CA, Zibetti RGM, Faria PCS, Noseda MD, Duarte MER et al. The antiviral activity of sulfated polysaccharides against dengue virus is dependent on virus serotype and host cell. Antivir Res. 2005; 66: 103-110.
11. Ono L, Wollinger W, Rocco IM, Combra TLM, Gorin PAJ, Sierakowski MR. In vitro and in vivo antiviral properties of sulfated galactomannans against yellow fever virus (BeH111 strain) and dengue 1 virus (Hawaii strain). Antivir Res. 2003; 60: 201-208.
12. Michelow IC, Dong M, Mungall BA, Michael Yantosca L, Lear C, Ji X et al. A novel l-ficoli/mannose-binding lecithin chimeric molecule with anhanced activity against Ebola virus. J Biol Chem. 2010; 285(32): 24729-24739.
13. Jain M, Ganju L, Katiyal A, Padwad Y., Mishra KP, Chanda S et al. Effect of Hippophae rhamnoides leaf extract against Dengue virus infection in human blood-derived macrophages. Phytomedicine. 2008; 15: 793-799.
14. Reis SRIN, Valente LMM, Sampaio AL, Siani AC, Gandini M, Azeredo EL et al. Immunomodulating and antiviral activities of Uncaria tomentosa on human monocytes infected with Dengue Virus-2. Int Immunopharmacol. 2008; 8: 468-476.
15. Heitzman ME, Neto CC, Winiarz E, Veisberg AJ, Hammond GB. Ethnobotany, phytochemistry and pharmacology of Uncaria (Rubiaceae). Phytochemistry. 2005; 66: 5-29.
16. Valente L. M. M. Cat's claw [Uncaria tomentosa (Willd.) DC. and Uncaria guianensis (Aubl.) Gmel.]: an overview of their more relevant aspects. Fitos. 2006; 2: 48-58
17. Liu Y, Yang Z, Deng H, Xiao H, Qu Ch. Separation and Anti-Hantaan Virus Activity of Extracts from Alternanthera philoxcroides in vitro and in vivo. Wuhan University J Nat Sci. 2007; 12(6): 1143-1147.
18. Meneses R, Ocazionez RE, Martinez JR, Stashenko EE. Inhibitory effect of essential oils obtained from plants grown in Colombia on yellow fever virus replication in vitro. ACMAs 2009; 8(8): 1-6.
19. Candurra NA, Maskin L, Damonte EB. Inhibition of arenavirus in vitro by phenotiazines. Antivil Res. 1996; 31: 149-158.
20. Chung D-H, Strouse JJ, Sun Y, Arterburn JB, Parker WB, Jonsson CB. Synthesis and anti-Hantaan virus activity of N1- 3-fluorophenylinosine. Antivir Res. 2009; 83: 80-85.
21. Bray M, Paragas J. Experimental therapy of filovirus infections. Antivir Res. 2002; 54: 1-17.
22. Bray M, Driscoll J, Huggins JW. Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor. Antivir Res. 2000; 45: 135-147.
23. Yermolina MV, Wang J, Caffrey M, Rong LL, Wardrop DJ. Discovery, synthesis, and biological evaluation of a novel group of selective inhibitors of filoviral entry. J Med Chem. 2011; 54(3): 765-781.
24. Simon M, Falk KI, Lundkvist Å, Mirazimi A. Exogenous nitric oxide inhibits Crimean Congo hemorrhagic fever virus. Virus Res. 2006; 120: 184-190.
25. Barrientos LG, O'Keefe BR, Bray M, Sanchez A, Gronenborn AM, Boyd MR. Cyanovirin-N binds to the viral surface glycoprotein, GP1,2 and inhibits infectivity of Ebola virus. Antivir Res. 2003; 58: 47-56.
26. Aman MJ, Kinch MS, Warfield K, Warren T, Yunus A, Enterlein S et al. Development of a broad-spectrum antiviral with activity against Ebola virus. Antivir Res. 2009; 83: 245-251.
27. Bouloy M, Flick R. Reverse genetics technology for Rift Valley fever virus: Current and future applications for the development of therapeutics and vaccines. Antivir Res. 2009; 84: 101-118.
28. Barradas JS, Errea MI, D'Accorso NB, Sepúlveda CS, Damonte EB. Imidazo [2,1-b] thiazole carbohydrate derivatives: Synthesis and antiviral activity against Junin virus, agent of Argentine hemorrhagic fever. Eur J Med Chem. 2011; 46: 259-264.
29. Smith DR, McCarthy S, Chrovian A, Olinger G, Stossel A, Geisbert TW et al. Inhibition of heat-shock protein 90 reduces Ebola virus replication. Antivir Res. 2010; 87: 187-194.
30. Kato D, Era S, Watanabe I, Arihara M, Sugiera N, Kimata K et al. Antiviral activity of chondroitin sulphate E targeting dengue virus envelope protein. Antivir Res. 2010; 88: 236-243.
31. Sepúlveda CS, Fascio ML, Mazzucco MB, Palacios MLD, Pellón RF, Garcia CC et al. Synthesis and evaluation of N-substituted acridones as antiviral agent against haemorrhagic fever viruses. Antivir Chem Chemoth. 2008; 19: 41-47.
32. Deng H, Luo F, Zhong Q, Liu Y, Yang Z. Efficacy of arbidol on lethal hantaan virus infections in suckling mice and in vitro. Acta Pharm Sinic. 2009; 30: 1015-1024.
33. Delogu I, Pastorino B, Baronti C, Neugairede A, Bonnet E, de Lamballerie X. In vitro antiviral activity of arbidol against Chikungunya virus and characteristics of a selected resistant mutant. Antivir Res. 2011; 90: 99-107.
34. Maves RC, Oré R, McPorter KR, Kochel TJ. Immunogenicity and protective efficacy of a psoralen-inactivated dengue-1 virus vaccine candidate in Aotus nancymaae monkeys. Vaccine. 2011; 29: 2691-2696.
35. Näslund J, Lagerqvist N, Habjan M, Lundkvist Å, Evander M, Ahlm C et al. Vaccination with virus-like particles protects mice from lethal infection of Rift Valley Fever Virus. Virology. 2009; 385: 409-415.
36. Mandell RB, Kaukuntla R, Mogler LJK, Carzoli AK, Freiberg AN, Holbrook MR et al. A replication-incompetent Rift Valley fever vaccine: Chimeric virus-like particles protect mice and rats against lethal challenge. Virology 2010; 397: 187-198.
37. Rao M, Matyas GR, Griedar F, Anderson K, Jahrling PB, Alving CR. Cytotoxic T lymphocytes to Ebola Zaire virus are induced in mice by immunization with liposomes containing lipid A. Vaccine. 1997; 17: 2991-2998.
38. Sun J, DuFort Ch, Daniel M-Ch, Murali A, Chen Ch, Gopinath K, Stein B et al. Core-controlled polymorphism in virus-like particles. PNAS 2007; 104(4): 1354-1359.
39. Yang CE, Ye L, Compans RW: Protection against filoviruses infection: virus particle vaccines. Expert Rev Vacc. 2008; 79, 333-344.
40. Sun Y, Carrion R, Ye L, Wen Z, Ro Y-T, Brasky K et al. Protection against lethal challenge by Ebola virus-like particles produced in insect cells. Virology. 2009; 383: 12-21.
41. Daddario-DiCaprio KM, Geisbert TW, Geisbert JB, Ströher U, Hensley LE, Grolla A et al. Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet 2006; 367: 1399-404.
42. Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet 2011; 377: 849-62.
43. Geisbert TW, Hensley LE, Geisnert JB, Leung A, Johnson JC, Grolla A et al. Postexposure treatment of Marburg virus infection. Emerg Infect Dis. 2010; 16(7): 1119-1121.
44. Hensley LE, Malangu S, Asiedu C, Johnson J, Honko AN, Stanley D et al. Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus species. PLoS Pathogens 2010; 6(5); e1000904. doi:10.1371/journal.ppat.1000904.
45. Hayes EB. Is it time for a new yellow fever vaccine? Vaccine 2010; 28: 8073-8076
46. Monath TP, Fowler E, Johnson CT, Balser DOJ, Morin MJ, Sisti M et al. An inactivated cell-culture vaccine against Yellow Fever. N Engl J Med. 2011; 364: 1326-33.
47. Park K, Kim ChS, Moon K-T. Protection effectiveness of Hantavirus vaccine. Emerg Infect Dis. 2004; 10(12): 2218-22020.
48. Geisbert TW, Hensley LE, Kagan E, Yu EZ, Geisbert JB, Daddario-DiCaprio K et al. Postexposure protection of guinea pigs against a lethal Ebola virus challenge is conferred by RNA interference. JID 2006; 193: 1650-1657.
49. Fowler T, Bamberg S, Möller P, Klenk H-D, Meyer TF, Becker S et al. Inhibition of Marburg virus protein expression and viral release by RNA interference. J Gen Virol. 2005; 86: 1181-1188.
50. Enterlein S, Warfield KL, Swenson DL, Stein DA, Smith JL, Gamble SC et al. VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice. Antimicrob Agents Chemother. 2006; 50(30): 984-993.
51. Warren TK, Warfield KL, Wells J, Swenson DL, Donner KS, Van Tongeren SA et al. Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat Med. 2010; 16(9): 991-994.
52. Takada A, Ebihara H, Jones S, Feldmann H, Kawaoka Y. Protective efficacy of neutralizing antibodies against Ebola virus infection. Vaccine. 2007; 25: 993-999.
53. Lai M, Engle M, Keller T, Johnson S, Gorlatov S, Diamond MS et al. Monoclonal antibody produced in plants efficiently treats West Nile virus infection in mice. PNAS 2010; 107(6): 2419-2424.
54. Miller EH, Harrison JS, Radoshitzky SR, Higgins ChD, Chi X, Kuhn JH et al. Inhibition of Ebola virus entry by a C-peptide targeted to endosomes. J Biol Chem. 2011; 286: 15854-15861.
55. Geisbert TW, Hensley LE, Jahrling PB, Larsen T, Geisbert JB, Paragas J et al. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet 2003; 362: 1953-58.
56. Carette JE, Raaben M, Wong AC, Herbert AS, Obernosterer G, Mulherkar N et al. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature 2011; 477: 340-343.
57. Kolodziej M, Joniec J, Bartoszcze M, Mirski T, Gryko R. Peptydy - nowe mozliwosci zwalczania zakazen wirusowych (Peptides - a new strategy for combating viral infections). Przegl Epidemiol. 2011; 65: 477-482.